Skip to the rundown
GetYourBrief
Search

Week brief · November 9 to 15, 2026

Biotech news, week of November 9, 2026

In the week of November 9 to 15, 2026 the Biotech desk recorded 7 news events on 4 days. Clinical trial led with 4.

The most covered stories of the week

  1. Nov 9 Eli Lilly plans FDA filing for Foundayo in sleep apnea after trial 2
  2. Nov 9 Temple's ageing claims rest on internal studies, Goyal says 2
  3. Nov 9 financialcontent.com: “AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights” 2
  4. Nov 10 FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor 2
  5. Nov 11 Miro says TGA audit of StemSmart manufacturing is complete 2
  6. Nov 14 WA biotech's mother-of-pearl bone graft clears FDA review 2
  7. Nov 14 Regeneron holds $16 billion in cash and trades near 20 times earnings 2

Monday, November 9, 2026

  1. 01

    Eli Lilly plans FDA filing for Foundayo in sleep apnea after trial

    2 outlets · first: STAT News Clinical trial

    Machine summary Two late-stage studies showed Foundayo, Eli Lilly's oral GLP-1 tablet, significantly lessened the severity of obstructive sleep apnea among obese patients, according to the company, which said it intends to file the findings with the FDA by year's end. The program tested 363 patients unable or unwilling to use positive airway pressure therapy and 349 patients who stayed on that therapy during the trial. STAT News reported the pill helped alleviate the condition but does not appear as effective as Lilly's injectable Zepbound.

    1. The program comprised two studies: 363 patients unable or unwilling to use positive airway pressure therapy, and 349 patients who had used that therapy for at least three months at screening and continued it
    2. Lilly said it intends to file, with the FDA and before the end of the year, results for the once-a-day pill meant for moderate-to-severe obstructive sleep apnea in adults who are obese or overweight.
    3. STAT News reported the pill helped alleviate sleep apnea in the two studies but does not appear as effective as Lilly's injectable Zepbound
    4. The National Council on Aging figures cited by CNBC put obstructive sleep apnea at nearly 1 billion adults globally, including 80 million people aged 20 and over in the U.S.

    Reported by STAT News and CNBC.

  2. 02

    Temple's ageing claims rest on internal studies, Goyal says

    2 outlets · first: kanthalaraghu.in Clinical trial

    Machine summary Deepinder Goyal's Temple wearable claims to measure brain blood flow and to provide insight into ageing, and the reports cite no peer-reviewed research behind those claims. Goyal said the company has run internal studies and committed to publishing peer-reviewed work in the future. Medical professionals dispute the claims, The Economic Times reported.

    1. Temple is a forehead-worn wearable priced at around ₹85,000 that claims to measure brain blood flow and physiological signals, according to reports
    2. The device records speech for AI through bone conduction and delivers notifications through vibration, per users who ordered it
    3. In an X post dated Nov. 8, 2026, Goyal wrote that Temple is not made for India and is aimed at the global market, projecting India at less than 1% of sales
    4. Goyal described the device as experimental, aimed at early adopters rather than a mass-market finished product
    5. Medical professionals dispute the device's claims and question the scientific validation behind its technologies, The Economic Times reported

    Reported by The Economic Times and kanthalaraghu.in.

  3. 03

    Coverage recordfinancialcontent.com: “AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights”

    2 outlets · first: financialcontent.com Clinical trial

    The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).

    Reported by financialcontent.com and Rutland Herald.

    • AN2 Therapeutics, Inc.

Tuesday, November 10, 2026

  1. 04

    FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor

    2 outlets · first: TradingView Fda approval

    Machine summary The FDA approved pimicotinib (Pimjetmi), an oral selective CSF-1R inhibitor, for symptomatic tenosynovial giant cell tumor in patients whose disease carries high surgical risk, MedPage Today reported. The phase III MANEUVER trial randomized 94 patients 2:1 and recorded an objective response rate of 54% at week 25 versus 3% on placebo (P<0.0001), with two-year durability of 76-78%. Pimicotinib becomes the third approved drug for the tumor type, after pexidartinib in 2019 and vimseltinib in 2025.

    1. The FDA approved pimicotinib (Pimjetmi), an oral selective CSF-1R inhibitor, for symptomatic tenosynovial giant cell tumor where surgery carries high risk of worsening functional limitation or severe morbidity, MedPage Today reported.
    2. In the phase III MANEUVER trial, 94 patients with unresectable TGCT were randomized 2:1 to pimicotinib or placebo; objective response rate at week 25 was 54% versus 3% (P<0.0001).
    3. Two-year MANEUVER results showed response durability of 76-78% with pimicotinib, along with improvements in pain, stiffness and range of motion, the report states.
    4. Pimicotinib is the third FDA-approved drug for TGCT, after pexidartinib (Turalio), approved in 2019, and vimseltinib (Romvimza), approved in 2025.
    5. TGCT is a soft-tissue tumor of joint synovium, bursae or tendon sheaths. Reports give a median patient age of 38.

    Reported by MedPage Today and TradingView.

    • Tenosynovial giant cell tumor (TGCT)
    • CSF-1R (colony stimulating factor-1 receptor)
    • Vimseltinib (Romvimza)
    • Pexidartinib (Turalio)
    • EMD Serono
    • Pimjetmi

Wednesday, November 11, 2026

  1. 05

    Miro says TGA audit of StemSmart manufacturing is complete

    2 outlets · first: BiotechDispatch Clinical trial

    Machine summary Miro Sciences, formerly NeuroScientific Biopharmaceuticals, said the TGA completed an audit of StemSmart manufacturing at Brisbane contract manufacturer Q-Gen Cell Therapeutics. The company said the inspection clears the way to scale clinical-grade production ahead of a phase two trial in refractory Crohn's disease it aims to begin before the end of 2026. The report describes Q-Gen as holding its own TGA cell therapy manufacturing licence, with more than 25 years of experience and 13 cleanrooms.

    1. Miro Sciences, formerly NeuroScientific Biopharmaceuticals, said the TGA completed an audit of StemSmart manufacturing at Q-Gen Cell Therapeutics in Brisbane
    2. StemSmart is a patented stem cell platform developed at Royal Perth Hospital using stem cells from adult human donor bone marrow
    3. The company says StemSmart cells are universal donor cells requiring no patient matching, positioning it as an off-the-shelf intravenous infusion
    4. Miro has said it aims to begin a phase two clinical trial in refractory Crohn's disease before the end of 2026
    5. According to the report, Q-Gen possesses its own TGA licence to manufacture cell therapy, brings over 25 years of experience, and runs 13 cleanrooms.

    Reported by BiotechDispatch and thewest.com.au.

Saturday, November 14, 2026

  1. 06

    WA biotech's mother-of-pearl bone graft clears FDA review

    2 outlets · first: abc.net.au Fda approval

    Machine summary Marine Biomedical, founded in 2021 by Willie Creek Pearls and the University of Western Australia, has received FDA clearance for PearlBone, a bone graft substitute built from nacre. Its CEO said the product was compared against an established market graft and shown to be as safe and efficacious as the predicate device.

    1. The report describes PearlBone as the first bone graft substitute developed from nacre, a material previously used for jewellery, buttons and ornamentation
    2. The US bone grafts and substitutes sector is valued at US$1.1 billion (A$1.5 billion), and the US is described as the world's largest orthopaedics market
    3. In 2021, Marine Biomedical was founded through a collaboration linking Willie Creek Pearls, a Broome pearling business, with research expertise provided by the University of Western Australia.
    4. Kumar said further hurdles remain before US sales and that the company hopes to reach Australian customers in future and expand into dental work

    Reported by abc.net.au and via Google News.

    • University of Western Australia
    • Willie Creek Pearls
    • nacre (mother-of-pearl)
    • Marine Biomedical
    • PearlBone
  2. 07

    Regeneron holds $16 billion in cash and trades near 20 times earnings

    2 outlets · first: fool.com Pharma

    Machine summary The company has 16 approved or authorized products and reported record quarterly sales for Libtayo and Eylea HD.

    1. The stock climbed more than 40% over the past year, the article reports
    2. Regeneron has 16 approved or authorized products across immunology, ophthalmology and oncology, per the piece
    3. Record quarterly sales were reported for Libtayo, up 51% to $550 million, and Eylea HD, up 62% to $699 million
    4. Sales of the original Eylea have decreased due to competition, while the higher-dose Eylea HD is taking some of that market share, the article states
    5. Dupixent is sold in partnership with Sanofi and is named alongside Libtayo as a driver of gains

    Reported by fool.com and AOL.com.

    • Sanofi
    • Dupixent
    • Eylea
    • Eylea HD
    • Libtayo

Summaries and key facts are machine summaries of the reports linked with them; outlets, times and counts come from those reports. How a rundown is built.

What kind of news was it?

  1. Clinical trial 4
  2. Fda approval 2
  3. Pharma 1

Sources: the outlets' reports linked on this page; counts and times from GetYourBrief's record of those reports (methodology).